MA45686A - Formes salines de 4-cyano-n-(2-(4,4-diméthylcyclohex-1-en-1-yl)-6-(2,2,6,6-tétraméthyltétrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide - Google Patents

Formes salines de 4-cyano-n-(2-(4,4-diméthylcyclohex-1-en-1-yl)-6-(2,2,6,6-tétraméthyltétrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide

Info

Publication number
MA45686A
MA45686A MA045686A MA45686A MA45686A MA 45686 A MA45686 A MA 45686A MA 045686 A MA045686 A MA 045686A MA 45686 A MA45686 A MA 45686A MA 45686 A MA45686 A MA 45686A
Authority
MA
Morocco
Prior art keywords
tetramethyltetrahydro
dimethylcyclohex
pyran
carboxamide
pyridin
Prior art date
Application number
MA045686A
Other languages
English (en)
Inventor
David Breslin
Nagy E Fawzy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA45686A publication Critical patent/MA45686A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA045686A 2016-07-18 2017-07-17 Formes salines de 4-cyano-n-(2-(4,4-diméthylcyclohex-1-en-1-yl)-6-(2,2,6,6-tétraméthyltétrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide MA45686A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662363657P 2016-07-18 2016-07-18

Publications (1)

Publication Number Publication Date
MA45686A true MA45686A (fr) 2019-05-22

Family

ID=59631848

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045686A MA45686A (fr) 2016-07-18 2017-07-17 Formes salines de 4-cyano-n-(2-(4,4-diméthylcyclohex-1-en-1-yl)-6-(2,2,6,6-tétraméthyltétrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide

Country Status (7)

Country Link
US (4) US10266522B2 (fr)
EP (1) EP3484873A1 (fr)
AR (1) AR109080A1 (fr)
MA (1) MA45686A (fr)
TW (1) TW201811326A (fr)
UY (1) UY37339A (fr)
WO (1) WO2018017446A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6530173B2 (ja) * 2014-10-27 2019-06-12 株式会社ブリヂストン タイヤ
WO2018182527A1 (fr) * 2017-03-30 2018-10-04 National University Of Singapore Procédé de traitement de complications inflammatoires dans des maladies oculaires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
US20140151258A1 (en) * 2012-12-03 2014-06-05 Cryovac, Inc. Polymeric Films Comprising Biodegradable Polyester or Copolymer Thereof
AU2014235183B9 (en) * 2013-03-15 2018-04-05 Janssen Pharmaceutica Nv Substituted pyridine derivatives useful as c-fms kinase inhibitors

Also Published As

Publication number Publication date
US20180016264A1 (en) 2018-01-18
US10562892B2 (en) 2020-02-18
EP3484873A1 (fr) 2019-05-22
US20200140421A1 (en) 2020-05-07
US20210053951A1 (en) 2021-02-25
US20190194175A1 (en) 2019-06-27
US10858348B2 (en) 2020-12-08
TW201811326A (zh) 2018-04-01
WO2018017446A1 (fr) 2018-01-25
AR109080A1 (es) 2018-10-24
UY37339A (es) 2018-01-31
US10266522B2 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
DK3436444T3 (da) Heterocyklisk forbindelse
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA45646A (fr) Derives de benzimidazole comme des modulateurs de ror-gamma
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA42592A (fr) Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak
FR3056393B1 (fr) Orthese d'extension de machoires
MA49639A (fr) Polymorphes de 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one
IT201700051909A1 (it) Calandra perfezionata
DK3390407T3 (da) Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
MA50174A (fr) Formules de protéines de fusion vegfr-fc
DK3277287T3 (da) Blandinger af humane mælke-oligosaccharider, der omfatter 3 '-o-sialyllactose
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
DK3423060T3 (da) Imatinib til anvendelse til behandling af slagtilfælde
DK3450436T3 (da) Kondenseret heterocyklisk forbindelse
MA45686A (fr) Formes salines de 4-cyano-n-(2-(4,4-diméthylcyclohex-1-en-1-yl)-6-(2,2,6,6-tétraméthyltétrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide
DOS2018000079S (es) Paños quirúrgicos
DK3575293T3 (da) Ethansulfonatsalt af n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5- dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolincarboxamid
DK3515454T3 (da) Krystallinsk polymorf form af 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinan
DK3472149T3 (da) Heterocykliske prolinamidderivater
MA46464A (fr) Polymorphes de l'agoniste de récepteur muscarinique
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1